Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

222 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Incidence of Hepatocellular Carcinoma after Treatment with Sofosbuvir-Based or Sofosbuvir-Free Regimens in Patients with Chronic Hepatitis C.
Ogawa E, Nomura H, Nakamuta M, Furusyo N, Kajiwara E, Dohmen K, Kawano A, Ooho A, Azuma K, Takahashi K, Satoh T, Koyanagi T, Ichiki Y, Kuniyoshi M, Yanagita K, Amagase H, Morita C, Sugimoto R, Kato M, Shimoda S, Hayashi J. Ogawa E, et al. Among authors: kawano a. Cancers (Basel). 2020 Sep 11;12(9):2602. doi: 10.3390/cancers12092602. Cancers (Basel). 2020. PMID: 32933027 Free PMC article.
Efficacy of interferon-beta plus ribavirin combination treatment on the development of hepatocellular carcinoma in Japanese patients with chronic hepatitis C.
Ikezaki H, Nomura H, Furusyo N, Ogawa E, Kajiwara E, Takahashi K, Kawano A, Maruyama T, Tanabe Y, Satoh T, Nakamuta M, Kotoh K, Azuma K, Dohmen K, Shimoda S, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group. Ikezaki H, et al. Among authors: kawano a. Hepatol Res. 2016 Mar;46(3):E174-80. doi: 10.1111/hepr.12555. Epub 2015 Sep 2. Hepatol Res. 2016. PMID: 26189962
Diabetes Mellitus Prevents an Improvement in the Serum Albumin Level During Interferon-free Sofosbuvir-based Therapy for Chronic Hepatitis C Patients: A Multi-institutional Joint Study.
Kawano A, Shigematsu H, Miki K, Ichiki Y, Morita C, Yanagita K, Takahashi K, Dohmen K, Nomura H, Ishibashi H, Shimoda S. Kawano A, et al. Intern Med. 2018 Jun 1;57(11):1533-1542. doi: 10.2169/internalmedicine.9857-17. Epub 2018 Jan 11. Intern Med. 2018. PMID: 29321441 Free PMC article.
Cost-effectiveness analysis of sofosbuvir plus ribavirin in patients with genotype 2 chronic hepatitis C: an analysis with real world outcomes from a multicentre cohort in Japan.
Igarashi A, Furusyo N, Ogawa E, Nomura H, Dohmen K, Higashi N, Takahashi K, Kawano A, Azuma K, Satoh T, Nakamuta M, Koyanagi T, Kato M, Shimoda S, Kajiwara E, Hayashi J. Igarashi A, et al. Among authors: kawano a. BMJ Open. 2019 Jun 19;9(6):e023405. doi: 10.1136/bmjopen-2018-023405. BMJ Open. 2019. PMID: 31221866 Free PMC article.
Development of Hepatocellular Carcinoma in Patients Aged 75-84 Years With Chronic Hepatitis C Treated With Direct-Acting Antivirals.
Ogawa E, Nomura H, Nakamuta M, Furusyo N, Kajiwara E, Dohmen K, Kawano A, Ooho A, Azuma K, Takahashi K, Satoh T, Koyanagi T, Ichiki Y, Kuniyoshi M, Yanagita K, Amagase H, Morita C, Sugimoto R, Kato M, Shimoda S, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group. Ogawa E, et al. Among authors: kawano a. J Infect Dis. 2022 Aug 26;226(3):431-440. doi: 10.1093/infdis/jiaa359. J Infect Dis. 2022. PMID: 32584386 Free PMC article.
Long-term assessment of recurrence of hepatocellular carcinoma in patients with chronic hepatitis C after viral cure by direct-acting antivirals.
Ogawa E, Nakamuta M, Furusyo N, Kajiwara E, Dohmen K, Kawano A, Ooho A, Azuma K, Takahashi K, Satoh T, Koyanagi T, Yamashita N, Ichiki Y, Yamashita N, Kuniyoshi M, Yanagita K, Amagase H, Morita C, Sugimoto R, Kato M, Shimoda S, Nomura H, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group. Ogawa E, et al. Among authors: kawano a. J Gastroenterol Hepatol. 2022 Jan;37(1):190-199. doi: 10.1111/jgh.15659. Epub 2021 Aug 23. J Gastroenterol Hepatol. 2022. PMID: 34374128 Free PMC article.
Telaprevir-based triple therapy for chronic hepatitis C patients with advanced fibrosis: a prospective clinical study.
Ogawa E, Furusyo N, Nakamuta M, Kajiwara E, Nomura H, Dohmen K, Takahashi K, Satoh T, Azuma K, Kawano A, Tanabe Y, Kotoh K, Shimoda S, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group. Ogawa E, et al. Among authors: kawano a. Aliment Pharmacol Ther. 2013 Nov;38(9):1076-85. doi: 10.1111/apt.12494. Epub 2013 Sep 17. Aliment Pharmacol Ther. 2013. PMID: 24099469 Free article. Clinical Trial.
Effectiveness of triple therapy with simeprevir for chronic hepatitis C genotype 1b patients with prior telaprevir failure.
Ogawa E, Furusyo N, Dohmen K, Kajiwara E, Kawano A, Nomura H, Takahashi K, Satoh T, Azuma K, Nakamuta M, Koyanagi T, Kotoh K, Shimoda S, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group. Ogawa E, et al. Among authors: kawano a. J Viral Hepat. 2015 Dec;22(12):992-1001. doi: 10.1111/jvh.12427. Epub 2015 Jun 15. J Viral Hepat. 2015. PMID: 26075320
Short-term risk of hepatocellular carcinoma after hepatitis C virus eradication following direct-acting anti-viral treatment.
Ogawa E, Furusyo N, Nomura H, Dohmen K, Higashi N, Takahashi K, Kawano A, Azuma K, Satoh T, Nakamuta M, Koyanagi T, Kato M, Shimoda S, Kajiwara E, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group. Ogawa E, et al. Among authors: kawano a. Aliment Pharmacol Ther. 2018 Jan;47(1):104-113. doi: 10.1111/apt.14380. Epub 2017 Oct 16. Aliment Pharmacol Ther. 2018. PMID: 29035002
Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C.
Furusyo N, Ogawa E, Nakamuta M, Kajiwara E, Nomura H, Dohmen K, Takahashi K, Satoh T, Azuma K, Kawano A, Tanabe Y, Kotoh K, Shimoda S, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group. Furusyo N, et al. Among authors: kawano a. J Hepatol. 2013 Aug;59(2):205-12. doi: 10.1016/j.jhep.2013.03.020. Epub 2013 Mar 28. J Hepatol. 2013. PMID: 23542346 Clinical Trial.
222 results